{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-079009","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.514553+00:00","generated_at":"2026-05-20T05:43:57.891096+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Karyopharm shareholders approve 450,000 share increase to equity plan at annual meeting","bullets":["Elected Garen G. Bohlin and Zhen Su as Class III directors with 3,066,819 and 3,191,845 votes for, respectively.","Approved amendment to 2022 equity plan adding 450,000 shares; 2,606,928 for, 1,103,365 against, 344,880 abstain.","Advisory vote on named executive officer compensation passed: 2,716,951 for, 1,041,611 against, 296,611 abstain.","Advisory vote on say-on-pay frequency favored every year (3,263,514 votes); Board adopted annual frequency.","Ratified Ernst & Young as independent auditor for FY2025: 6,237,926 for, 210,714 against, 115,566 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-079009","json":"https://secwatch.observer/filing/0000950170-25-079009.json","markdown":"https://secwatch.observer/filing/0000950170-25-079009.md","text":"https://secwatch.observer/filing/0000950170-25-079009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025079009/0000950170-25-079009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025079009/kpti-20250528.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T05:43:57.891096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}